Hereditary papillary RCC (HPRC) — what an inherited MET gene change actually means

HPRC is a rare inherited condition in which a change in a single gene, present from birth in every cell, makes papillary kidney tumours much more likely. It is not the cancer itself that is inherited but the gene change that removes one of the safeguards. Two things set it apart from ordinary papillary kidney cancer: the tumours are usually multiple rather than single, and they often appear in both kidneys and at a younger age than kidney cancer normally does. The tumours are of the papillary kind that pathologists have long called type 1. The great majority of papillary kidney cancers are not this condition; they arise by chance in one person and are not passed on.

Usually not. Most papillary renal cell carcinoma is sporadic, meaning it arose by chance in one person from faults that built up in a single kidney cell over many years, and nothing was passed on to anyone. Only a small minority of cases sit inside an inherited syndrome. What makes a specialist think about an inherited cause is the pattern rather than the fact of one diagnosis: several separate tumours instead of one, tumours in both kidneys, a diagnosis at a notably young age, or more than one close relative affected on the same side of the family. One older relative with a single papillary tumour and none of those features is the common and reassuring picture.

MET carries the instructions for a receptor that sits on the surface of kidney cells and tells them when to grow. In hereditary papillary RCC the inherited change leaves that growth switch stuck partly on, so cells that should stay quiet keep dividing. Because the change is present in every kidney cell from birth, tumours can start independently in many places at once, which is why this condition tends to produce multiple tumours in both kidneys rather than one. The same pathway can also be disturbed by chance in tumours that are not inherited at all. Knowing which is the case matters, because it decides whether the rest of the family needs advice.

Both are inherited conditions that raise kidney cancer risk, but they involve different genes, produce different tumour types and behave differently outside the kidney. VHL disease affects several organs, so growths in the eye and nervous system, adrenal tumours and pancreatic cysts are part of the picture, and the kidney tumours are of the clear cell kind. Hereditary papillary RCC characteristically keeps to the kidney: there are no skin, eye or nervous system features to look for, and the tumours are papillary rather than clear cell. That absence of clues elsewhere is exactly why this condition is easy to miss, and why the kidney pattern itself has to do the work of raising suspicion.

Not everyone with papillary kidney cancer needs it. NCCN guidance recommends genetic risk evaluation for people diagnosed at a young age, for those with tumours in both kidneys or more than one separate tumour, and for those with close relatives affected. The step before any test is genetic counselling, which is led in house by medical oncology at CION: the family history and the pathology are gone through properly first, and testing is offered only where a result would change what happens next. That matters because the answer affects your relatives as well as you. Where nothing meets the criteria, counselling ends with a clear explanation of why a test would not help.

The aim is different from ordinary kidney cancer care: because new tumours can keep appearing over a lifetime, the kidneys have to be protected as carefully as the cancer is treated. Confirmed carriers and at risk relatives are offered planned imaging on a schedule set by the team, which CION arranges and reports in house. Small tumours are often watched rather than removed straight away. When an operation is needed it is kidney sparing wherever possible, and kidney surgery and ablation are coordinated by CION with specialist urology, uro oncology and interventional radiology partner centres rather than delivered in house. If disease ever becomes advanced, targeted therapy directed at the MET pathway is a recognised option class, given by medical oncology at CION.